CMS
Helps ZOLL positioning the existing und forthcoming products value to ensure optimal patient access and pricing/reimbursement. From early stages pre-marketing, throughout the products’ lifecycle, support the commercial team regarding reimbursement and dossier submissions to HAS and other areas related to value demonstration with scientific leaders & governmental & health authority decision makers.
Role Overview
Provide strategic / medical / technical expertise:
• Helps ZOLL positioning the existing und forthcoming products value to ensure optimal patient access and pricing/reimbursement. From early stages pre-marketing, throughout the products’ lifecycle, support the commercial team regarding reimbursement and dossier submissions to HAS and other areas related to value demonstration with scientific leaders & governmental & health authority decision makers.
• With the anticipation of health technologies assessments drives the necessary appropriate outcomes research trials/registries to support efficient market access strategies for the ZOLL CMS products.
• Utilizes previous insights and experiences in plans and deliverables gaining the confidence of both internal ZOLL stakeholders, French Governmental institutions, external HTA bodies (HAS/RIZIV-INAMI), patient organisations and other reimbursement authorities.
• Provides early input into business development and commercial teams to ensure payer requirements are adequately met though evidence generation and commercial strategy development processes
• Responsible for establishing stable relationships with customers and scientific opinion leaders, work closely with France/Belgium thought leaders in cardiology and scientific societies.
• Develops France/Belgium market access/HEOR strategy and associated evidence generation plans to optimize market access and product uptake.
• Develops value propositions to ensure ZOLL has a compelling value story and the right evidence at the right time to support existing & new product’s value proposition to payers, providers, and other key stakeholders.
Foster collaborations:
• Works closely with the commercial organisation / EMEA marketing to reinforce the credibility of ZOLL in the context of market development activities and pre-project activities.
• Manages the collaborations with external consulting companies in the context of specific projects.
• Reports directly to the EMEA Director health policy and works closely with the EMEA health policy team to ensure an integrated offer to HTA bodies.
• Works closely with the Managing Director France and the French marketing team to ensure appropriate integration of HEOR parameters into daily business.
Requirements
• Past work experience including at least 5+ years in at least one of the following:
• The medical device industry in a health economics, governmental affairs and or outcomes research and/or market access focused role
• Consulting, in a health economics governmental affairs and outcomes research and/or market access focused role ideally in cardiology
• Experience in both governmental affairs and market access (France + Belgium) markets preferred
• French (+ English) language and French market experience
• A Masters’ Degree in a relevant discipline is preferred (e.g., Ph.D., MD, or M.Sc. in Biomedical Engineering, Epidemiology, Health Economics, Public Health, or Health Policy).
• Existing network to relevant institutions in France (for example, HAS, CNENDIMTS; CEESP; CEPS)
• Deep understanding of Health Economics, meta-analyses, retrospective and prospective data generation activities, clinical trial methodologies, relative effectiveness, and all other ingredients of an optimal value proposition and professional HTA or price & reimbursement submissions are required.
• Deep appreciation of science and ability to translate scientific information into strategy is required.
• An ability to manage multiple demands and priorities on time, influence without authority, gain alignment and drive decision making is required.
• Excellent communication skills with a strong track record of producing results in a matrix-based environment are required.
• Travel: Approximately 30% of the time
